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Abstract: One of the great advances in the treatment of HIV-1 infection was the development 
of the highly active antiretroviral therapy (HAART). Although this treatment strategy is highly 
effective in many individuals, interpatient variability of drug response and high incidences 
of short- and long-term toxicities remain significant problems associated with this treatment. 
Logically, pharmacogenetic differences among HIV-1-infected individuals are thought to 
represent important factors contributing to antiretroviral drug response. Studies have identified 
polymorphisms in drug-metabolizing enzymes, drug transporters, and most recently the human 
leukocyte antigen locus that appears to have significant effects on the clinical outcomes of antiret-
roviral therapy. Furthermore, some studies have shown that many of these crucial polymorphisms 
are more likely or less likely in certain populations. This review investigates the potential role 
of pharmacogenomics in the management of HIV-1 infection in people of African descent.
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Introduction
HIV/AIDS has claimed the lives of more than 25 million people worldwide, mostly 
within Africa. There have been remarkable advances in the treatment of HIV/AIDS 
during the last 20 years. Today there are over 20 antiretroviral agents representing 
five therapeutic drug classes, each with a unique mechanism of action.1 The first class 
of drugs that were used in antiretroviral therapy was nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTIs). This class of drugs inhibits reverse transcription by 
becoming incorporated into viral DNA while it is being synthesized thereby preventing 
elongation. Popular drugs in this class include zidovudine, lamivudine, and abacavir. 
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are another class of drugs that 
also inhibit reverse transcription. NNRTIs, however, achieve this by directly binding 
to viral reverse transcriptase, inhibiting its function. There are only two widely used 
drugs in this class, efavirenz (EFV) and nevirapine (NVP). The third major class of 
antiretroviral drugs are the protease inhibitors (PIs). These drugs inhibit the proteases 
that are needed by the virus to assemble new virons. Popular PIs include indinavir, 
ritonavir, and atazanavir. The remaining classes of drugs are integrase inhibitors, 
which prevent viral DNA from integrating into host DNA, and entry inhibitors, which 
prevent the virus from binding and fusing with the host cell membrane. The drugs in 
these classes are not as widely used as NRTIs, NNRTIs, and PIs. They are often used 
as additions to standard drug combinations or as salvage therapies after other drug 
classes have been exhausted.2,3Pharmacogenomics and Personalized Medicine 2009:2 94
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Highly active antiretroviral therapy (HAART) is the 
current standard of care for the treatment of HIV-1 infections. 
Current guidelines recommend that individuals begin on a 
HAART regime when their CD4 cell count dips into the 
range of 350–500 CD4 T cell/mm2. A typical HAART regime 
for initial therapy will consist of a combination of three or 
four drugs, usually two NRTIs with either an NNRTI or a 
ritonavir-boosted PI. Therapy is consider a success if it is able 
to suppress the viral load to a point below detection.4 Together 
these agents have been used in combination to treat HIV/
AIDS in millions of patients living with the virus. For many 
patients, this disease, once thought of as a death sentence, 
can now be thought of as a chronic disease, requiring 
life-long therapy.5 However, despite these successes, there 
are still many issues that need to be resolved, including the 
development of drug resistance and toxicity.
Individualization of medicine through the use of 
pharmacogenomics may help clinicians prescribe the 
most efficacious drug combination and dose for each of 
their patients.1 This type of optimization will result in 
increased efficacy and reduced risk for toxicity. Although 
pharmacogenomics has already made a clinical impact on 
HIV-1 therapy, the relationship between interindividual 
variability in response to anti-HIV-1 drugs and racial 
identity requires further exploration. Race/ethnicity can be 
a predictor of how an individual may respond to a particular 
drug due to the fact that alleles for certain genes that affect 
drug response can be more or less prevalent from population 
to population.2 The purpose of this review is to highlight 
potential areas where pharmacogenomics may be of use in 
both maximizing the efficacy and minimizing the toxicity 
of anti-HIV-1 therapy for individuals of African descent. 
Paying special attention to this population is of particular 
importance because individuals of African descent represent 
a disproportionate number of the new cases of HIV/AIDS 
that are presently being diagnosed. Additionally, Sub-Saharan 
Africa still represents the largest population of individuals 
with HIV/AIDS, and the majority of new cases reported 
worldwide are in this area.6 Unfortunately, however, the 
majority of clinical research is performed in countries like 
the United States where individuals of African descent are 
minorities, and this population is generally underrepresented 
in research.7
Polymorphisms are naturally occurring variants 
in the structures of genes and the products that they 
encode.8 Polymorphisms in a gene often have no visible or 
quantifiable affect on the functioning of the protein product. 
Sometimes, however, variation in a particular gene can result 
in altered function of the protein product. Polymorphisms 
can be of importance to pharmacotherapy when they occur 
in genes encoding drug-metabolizing enzymes, drug receptor 
proteins, and other proteins involved in drug response or 
disease progression. A single-nucleotide polymorphism 
(SNP) is a polymorphism is a single nucleotide difference 
that exists between two alleles of the same gene. While this 
change may seem minute, if it is in a critical spot it can vastly 
alter the functioning of the protein product. Many of the 
polymorphisms discussed in this article are SNPs. The study 
of the impact of human genetic variation upon individual 
responses to antiretroviral drugs is complex. It is difficult 
to explain the functional impact of human genetic variation 
in most cases, and more importantly, these polymorphisms 
do not act independently to influence disease evolution or 
treatment response.9
Pharmacogenomics  
and hypersensitivity
Hypersensitivity reactions are a major concern for patients 
being treated with antiretrovirals. A drug hypersensitivity 
reaction is an immunological reaction that an individual 
can develop in response to the administration of a certain 
drug. There are a wide range of symptoms that can 
accompany a hypersensitivity reaction, including serum 
sickness, hypotension, anaphylaxis, nausea, vomiting, 
diarrhea, and rash. Although only a small percentage of 
patients will experience hypersensitivity reactions during 
their treatment, some reactions can be very severe and 
even fatal.10
A number of human leukocyte antigen (HLA) genes have 
been linked to hypersensitivity reactions to antiretrovirals. 
HLA genes are found in region of the mammalian genome 
known as the major histocompatability complex (MHC).11 
HLA genes are expressed on the cell surface and display self 
and nonself antigens to T cells. When a drug is administered to 
a patient there is a possibility that the drug or some metabolite 
that is generated from the drug will end up being presented 
on the cell surface by an HLA protein. If the immune system 
recognizes this antigen as nonself, a hypersensitivity reaction 
may occur. The MHC itself is divided into three regions: I, II, 
and III. The HLA-A, HLA-B, and HLA-C genes can be found 
in region I, whereas HLA-D is located in region II. Genetic 
variation in HLA-B has been linked to the risk of developing 
antiretroviral hypersensitivity reactions, especially to the NRTI 
abacavir. One polymorphism in particular, HLA-B*5701, has 
been indicated as conferring a high risk for abacavir-induced 
hypersensitivity reactions.12–15Pharmacogenomics and Personalized Medicine 2009:2 95
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Approximately 5%–8% of patients who are treated with 
abacavir develop a drug hypersensitivity reaction within six 
weeks of treatment initiation. The symptoms of an abacavir 
hypersensitivity reaction can include fever, rash, diarrhea, 
and flu-like aches. In rare cases, abacavir hypersensitivity 
reactions can be fatal.16 Screening for the HLA-B*5701 allele 
has proven to be a valuable and cost-effective measure that 
clinicians can take to reduce the incidence of hypersensitivity 
reactions in their patients.13,15
Many of the studies performed in recent years that have 
reported on HLA-B*5701 offer conflicting data regarding 
how sensitive this marker is for predicting the occurrence of 
abacavir-induced hypersensitivity reactions. In a retrospective 
case-controlled study (n = 200) Hetherington and colleagues 
found HLA-B*5701 to be present in 46% of patients 
with hypersensitivity and in 4% of controls.14 Similarly, 
in an observational study (n = 63), Hughes and colleagues 
reported that 46% of abacavir-hypersensitive patients were 
positive for HLA-B*5701, compared to 10% of controls.15 
One study of the Western Australia HIV Cohort (n = 260) 
reported no detected cases of abacavir hypersensitivity in 
HLA-B*5701-negative patients.17 Mallal and colleagues 
performed a study also utilizing participants from the Western 
Australia HIV Cohort (n = 200), and found that 78% of 
the patients with abacavir hypersensitivity were positive 
for HLA-B*5701, while only 2% of the nonhypersensitive 
patients were positive for HLA-B*5701.18
Although HLA-B*5701 screening is undoubtedly valuable 
in the clinical setting, the discrepancies in the sensitivity of 
this marker in predicting abacavir hypersensitivity across 
studies is puzzling. Furthermore, some researchers have 
suggested that this marker is not useful for predicting abacavir 
hypersensitivity reactions in certain populations, including 
individuals of African descent.15 Although many studies have 
included patients of African descent the conflicting results 
become even more untrustworthy due to small sample sizes. 
This is a result of the fact that patients of African descent are 
less likely to develop hypersensitivity reactions to abacavir and 
are low carriers of HLA*5701 with a prevalence of 2.5% in the 
population.19 Saag and colleagues effectively addressed these 
concerns in a study that included 130 Caucasian patients and 
69 patients of African descent who had all been classified as 
receiving a diagnosis of abacavir hypersensitivity. Forty-two 
Caucasian patients and five patients of African descent 
in this study and had shown a positive skin patch result, 
immunologically confirming abacavir hypersensitivity. Control 
subjects were racially matched and were selected on the basis 
of showing tolerance to abacavir for 12 weeks or more.12
All subjects were screened for HLA-B*5701. Of the 
patients who had immunologically confirmed abacavir 
hypersensitivity (via skin patch test) 100%, in both groups 
(42 Caucasian patients and 5 patients of African descent), 
were positive for HLA-B*5701. The screen for the whole 
group revealed that 44% of the Caucasian patients and 14% of 
the patient of African descent who were given the diagnosis of 
abacavir hypersensitivity were positive for HLA-B*5701.12
This study suggests that the diagnosis of abacavir 
hypersensitivity can easily be muddled by other reactions 
that patients may be experiencing due to additional drugs 
that they are being administered. Indeed, when the abacavir 
hypersensitivity was immunologically confirmed, the 
sensitivity of HLA-B*5701 as a predictor for abacavir 
hypersensitivity was 100%. Although the number of African 
American patients included in this study was small with only 
five in the critical immunologically confirmed group, it still 
suggests that screening for HLA-B*5701 in this population 
is valid and crucial.
Pharmacogenomics  
and pharmacokinetics
The pharmacokinetics of a particular drug has much 
bearing on its efficacy and the risk of adverse side effects. 
Pharmacokinetics refers to the absorption, distribution, 
rate of action, metabolism, and excretion of routes of 
an administered drug. A number of genes affecting the 
pharmacokinetics of antiretroviral drugs will be discussed in 
this article, including: multidrug-resistant gene-1 (MDR1) 
and cytochrome P450 (CYP) genes (CYP2B6, CYP3 A4, 
and CYP3 A5).
MDR1 is a well characterized ABC-transporter of the 
MDR/TAP subfamily. There are a number of other names 
used to refer to this protein, including: p-glycoprotein (P-gp), 
ABCB1, and CD243. MDR1 functions as a broad spectrum 
efflux pump. MDR1 is expressed in most cell types and can 
be found at many of the important physiological barriers that 
drugs must traverse (ie, the intestinal epithelium, the capillary 
endothelium, and the proximal renal tubular cells. Thus, 
allelic variation at the mdr1 locus can have an influence on 
the absorption, distribution, and elimination of drugs.20
Cytochrome P450 takes part in phase I metabolism. Phase 
I metabolism can serve to either activate or inactivate a drug, 
while phase II metabolism usually involves conjugation 
reactions that serve to deactivate active metabolites/drugs. 
Phase I metabolism usually involves making the administered 
drug more polar through hydrolysis, oxidation, or reduction. 
Most oxidative reactions are carried out by cytochrome P450. Pharmacogenomics and Personalized Medicine 2009:2 96
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There 57 functional CYP genes found in the human 
genome which have been classified into 18 families and 
43 subfamilies. The CYP2 and CYP3 families are responsible 
for the metabolism of drugs and steroids.21 This paper will 
discuss CYP2B6, CYP3 A4, and CYP3 A5 in particular, with 
respect to the metabolism of antiretrovirals.
Polymorphisms in CYP2B6, CYP3 A4, CYP3 A5, 
and MDR1 are distributed differentially across Caucasian 
populations and populations of African descent. The CYP2B6 
516G→T polymorphism can be found in 3% of Caucasians and 
20% of individuals of African descent.3 The CYP3 A4*1B and 
CYP3 A5*3 polymorphisms are present at a rate of 5.9% and 
91.1% in Caucasians, respectively and 59.2% and 28.1% in 
individuals of African descent, respectively.22 Additionally, 
the 3435C→T polymorphisms found in MDR1 can be found 
in 49.7% of Caucasians and 12.6% of individuals of African 
descent.22 The presence of these polymorphisms has been 
found to affect the pharmacokinetics of antiretrovirals and 
is especially important for determining a patient’s response 
to EFV and NVP. Although these polymorphisms have not 
been found to affect the efficacy of either EFV or NVP, they 
do have a significant affect on the plasma concentration and 
half-life of these drugs. The heightened levels and elongated 
exposure of these drugs increases the amount of adverse 
side-effects, toxicity, and the need for discontinuation of 
treatment in patients.
Both Haas and colleagues23 and Ritchie and colleagues24 
found that the 3435C→T polymorphism in the MDR1 gene 
was associated with decreased risk of hepatotoxicity during 
treatment with NVP.23,24 Thus, individuals of African descent 
are at higher risk for developing hepatotoxicty during NVP 
treatment due to the low prevalence (12.6% vs 49.7% in 
Caucasians) of this polymorphism. In two consecutive studies, 
Haas and colleagues found that homozygousity for thiamine at 
position 516 in the CYP2B6 gene was associated with greater 
plasma exposure to EFV during treatment.3,25 This result 
was independently confirmed by Saitoh and colleagues in a 
study of 71 children undergoing EFV treatment.26 Ribaudo 
and colleagues measured EVF concentrations after treatment 
discontinuation. These researchers found that homozygousity 
for thiamine at position 516 in the CYP2B6 gene resulted 
in detectable EFV concentrations in 29% of patients, which 
was a significantly high percentage than individuals who 
were heterozygous or homozygous for guanine at this posi-
tion (5%).27 Greater plasma exposure increases the risk of 
individuals developing central nervous system side-effects 
to EFV . Individuals of African descent are therefore more 
prone to developing these adverse side-effects because of the 
increased prevalence of this polymorphism in the population 
(20% vs 3% in Caucasians).
Pharmacogenomics  
and atherogenic dyslipidemia
Many patients undergoing antiretroviral therapy develop 
atherogenic dyslipidemia which can put them at risk 
for experiencing acute cardiovascular events such as 
myocardial infarction, stoke, deep vein thrombosis, or 
pulmonary embolism.28–30 The development of atherogenic 
dyslipidemia is most commonly seen in patients receiving 
protease inhibitors as part of their antiretroviral therapy.28,31 
Lipid profiles of affected patients usually include increased 
low- and very-low-density lipoprotein particles (LDL and 
VLDL), decreased high-density lipoprotein (HDL) levels, 
and elevated triglyceride levels.32–34 They are most commonly 
found in patients receiving PI-based HAART regimes, 
especially those containing ritonavir.31,35 It is believed that 
PIs cause these lipid imbalances by modulating the normal 
production and degradation of apolipoproteins.32,36,37
Lipoprotein particles transport dietary lipids throughout 
the bloodstream. Lipoprotein particles can be distinguished 
by the type of apolipoproteins they contain. Apolipoproteins 
dictate the type of lipids that the particle will carry and 
also act as receptor ligands and enzyme co-factors, thereby 
controlling the metabolism and uptake of these particular 
lipids in various tissues.38 Apolipoproteins are divided into 
a number of major classes (apoA, apoB, apoC, etc.) which 
may be further divided into several subclasses.
LDL particles each contain a single apoB molecule. High 
LDL levels contribute to atherogenesis, because LDL particles 
are the major vehicle which delivers cholesterol from the 
liver to the site of growing atheromas.39 HDL particles, 
on the other hand, are thought to perform the opposite 
function, transporting cholesterol away from atheromas in 
the arteries and back to the liver where it can be excreted or 
metabolized. The most abundant apolipoproteins found in 
HDL are apoA-I and apoA-II. ApoA-IV is also found in HDL 
particles and, along with apoA-I, is an important player in 
terms of cholesterol and triglyceride levels.40 Apolipoprotein 
C (apoC) is found in VLDLs. ApoC-III is a member of the 
apoC family which can be found in HDL, LDL, and VLDL 
particles. ApoC-III inhibits lipoprotein lipase, thereby 
delaying the breakdown, metabolism, and hepatic clearance 
of triglyceride-rich lipoprotein particles.40 Logically, increases 
in the levels of apoC-III result in elevated triglyceride levels. 
SNPs in the promoter region of apoC-III at positions -455 
(C→T) and -482 (T→C), as well as a SNP at position Pharmacogenomics and Personalized Medicine 2009:2 97
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3238 (C→G) of the 3’ untranslated region (the SstI allele), 
have been associated with hypertriglyceridemia.41,42 ApoA-I, 
apoC-III, and apoA-IV are in linkage disequilibrium with each 
other, as they are found in a cluster on chromosome 11.43,44 
Apolipoprotein E (apoE) is found in chylomicrons, VLDL, 
and HDL particles and is involved in the transport and 
clearance of remnant lipoprotein particles. Associations 
between SNPs in apoE (the apoE ε4 and apoE ε2 alleles) and 
hyperlipidemia/cardiovascular events have been reported in 
non-HIV-infected individuals.45
Tarr and colleagues performed a study (n = 329) 
that analyzed three SNPs found in the ApoC3 gene 
(-455T→C, -482C→T, and Sst [3238] C→G) as well as the 
apoE ε4 and apoE ε2 alleles and concluded that individuals 
with unfavorable genotypes of ApoC3 or ApoE were at the 
highest risk for developing extremely high triglyceride levels 
while receiving antiretroviral therapy containing protease 
inhibitors.46 Fauvel et al similarly found that the three 
polymorphisms of ApoC3 were positively associated with 
developing atherogenic dyslipidemia during antiretroviral 
therapy with protease inhibitors (n = 60).47 An ambitious study 
by Foulkes and colleagues (n = 626) analyzed five different 
polymorphisms found in ApoC3: 455T→C, -482C→T, Sst 
[3238] C→G, intron I G→C, and Gly34Gly C→T. The goal 
of this study was to determine if there was evidence for 
race/ethnicity-specific effects on plasma lipid levels during 
HAART treatment. It has already been established that in the 
general population African Americans, on average, have more 
favorable lipid profiles than their Caucasian counterparts.48 
Foulkes and colleagues found variation in the distribution of 
ApoC3 polymorphisms among Caucasians and individuals of 
African descent.49 The frequencies of these polymorphisms 
in the two different racial/ethnic is summarized in Table 1. 
This study confirmed race as a significant predictor of 
baseline plasma lipid levels; individuals of African descent 
had lower levels of triglycerides and non-HDL cholesterol. 
Additionally, this study demonstrated that variations in 
the ApoC3 gene, distributed differentially among Cauca-
sians and individuals of African descent, influenced the 
development of dyslipidemia during antiretroviral therapy 
with protease inhibitors. Although the patients of African 
descent started with the lowest baseline triglyceride levels, 
this group showed the greatest increase in triglyceride 
levels during protease inhibitor exposure.49 Although this 
study does not provide any clear directives for clinical 
practice, it has provided evidence to justify similar studies. 
The data presented clearly indicates that conclusions from 
pharmacogenomic studies cannot be generalized across 
populations, and that the variable of race must be investi-
gated before guidelines are written.
Table 1 Frequency of polymorphisms that affect antiretroviral drug response in Caucasians and individuals of African descent.
HLA-dependent hypersensitivity reactions
Drug(s) Polymorphism Prevalence
Caucasian African descent
Abacavir HLA-B*5701 5.3%12 2.5%12
Adverse reactions resulting  
from altered pharmacokenetics
eFv, NvP CYP2B6 516G→T 3%3 20%3
eFv, NvP MDr1 3435C→T 49.7%22 12.6%22
eFv, NvP CYP3 A4*1B 5.9%22 59.2%22
eFv, NvP CYP3 A5*3 91.1%22 28.1%22
Atherogenic dyslipidemia
Protease inhibitor ApoC3 haplotype: -482C/-455T/intron i 
G/Gly34Gly C/Ssti (3238) C
45.5%49 10.8%49
Protease inhibitor ApoC3 haplotype: -482C/-455C/intron i 
G/Gly34Gly C/Ssti (3238) C
12.1%49 1.5%49
Protease inhibitor ApoC3 haplotype: -482C/-455T/intron i 
G/Gly34Gly T/Ssti (3238) C
10.5%49 6.3%49
Protease inhibitor ApoC3 haplotype: -482T/-455C/intron i 
C/Gly34Gly C/Ssti (3238) C
12.4%49 57.1%49
Protease inhibitor ApoC3 haplotype: -482T/-455C/intron i 
C/Gly34Gly T/Ssti (3238) G
8.2%49 8.2%49Pharmacogenomics and Personalized Medicine 2009:2 98
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Discussion
This review has discussed race-specific genetic variation 
at a number of loci which affects the tolerance and rate of 
adverse side-effects among HIV-infected patients undergoing 
standard HAART therapy. Individuals of African descent fare 
better than their Caucasian counterparts in terms of abacavir 
hypersensitivity reactions due to the fact that the prevalence of 
the HLA-B*5701 polymorphism is lower in this population. 
Clinical screening for HLA-B*5701 is currently utilized with 
much success. A number of studies however, have raised the 
question as to whether this type of screen is necessary and 
effective for individuals of African descent. A recent study by 
Saag and colleagues has suggested that this type of screening 
is in fact valuable and warranted for this population.12
Discontinuation of EFV- or NVP-based treatments due to 
adverse side-effects has been a major problem in individuals 
of African descent. This phenomenon has resulted in poor 
clinical outcomes for this population. Indeed, there is 
pharmacogenomic data suggesting that the genetics of this 
population lends them to experience elevated and prolonged 
exposure to EFV and NVP during treatment. This increased 
exposure leads to the increase in observed adverse events in 
these individuals. Further research should be conducted to find 
ways to make EFV and NVP treatment safer for this group.
Individuals of African descent enjoy more favorable lipid 
profiles than their white peers. However, it is worrisome and 
intriguing that this group appears to have the most marked 
increase in triglyceride levels during protease inhibitor treatment. 
Further research should be done to understand the molecular 
and genetic root for this phenomenon, as it may help to make 
treatment more efficacious and safe for all populations.
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